Niraparib and Dostarlimab in HRD Solid Tumors

Summary

This is an open-label, single-arm, Phase 2 study which will evaluate the efficacy and safety of niraparib and dostarlimab (TSR-042) combination in patients with metastatic, recurrent, or unresectable solid tumor with a pathogenic, or presumed pathogenic, somatic homologous recombination deficiency (HRD) gene mutation

Timeline

Start

2021-11-29

Primary completion

2024-08

Completion

2025-08

Drugs

Indications